Researchers
-
Begoña Pina Marín
Ophthalmology
-
Carlos Luis Moser Würth
Ophthalmology
-
Carlos Martínez Belló
Ophthalmology
-
Diana Paola Mora Ramirez
Ophthalmology
-
Joan Josep Escobar Barranco
Ophthalmology
-
Josep Badal Lafulla
Ophthalmology
Phd -
Luis Amselem Gómez
Ophthalmology
-
Magela Garat Chifflet
Ophthalmology
-
Manel Fernández Bonet
Ophthalmology
-
Monica Lecumberri López
Ophthalmology
-
Rafael Alcubierre Bailac
Ophthalmology
-
Sabrina Bojados
Ophthalmology
-
Stephanie Carrillo
Ophthalmology
Contact the group
Form
Projects
-
Ophthalmology
Researcher
- Year 2015
- Comprehensive Care Center Dos de Maig Hospital
Evaluation of physician and patient knowledge of information on the safety and safe use of Aflibercept in Europe: Postauthorization observational study,
-
DISTRICT ATTORNEY:
Bayer Healthcare Pharmaceuticals Inc.
-
TYPE E:
EPA
-
- Year 2015
- Comprehensive Care Center Dos de Maig Hospital
A two-year, randomized, double-masked, multicenter, two-group study to compare the efficacy and safety of RTH258 6 mg in combination with aflibercept in subjects with exudative age-related macular degeneration,
-
DISTRICT ATTORNEY:
Alcon Research, Ltd.
-
TYPE E:
RD2004
-
- Year 2015
- Dos de Maig Hospital Integral Care Center
A two-year, randomized, double-masked, multicenter, two-group study to compare the efficacy and safety of RTH258 6 mg in combination with aflibercept in subjects with exudative age-related macular degeneration,
-
DISTRICT ATTORNEY:
Alcon Research, Ltd.
-
TYPE E:
RD2004
-
- Year 2015
- Comprehensive Care Center Dos de Maig Hospital
Evaluation of physician and patient knowledge of information on the safety and safe use of Aflibercept in Europe: Postauthorization observational study,
-
DISTRICT ATTORNEY:
Bayer Healthcare Pharmaceuticals Inc.
-
TYPE E:
EPA
-
- Year 2015
- Dos de Maig Hospital Integral Care Center
Evaluation of physician and patient knowledge of information on the safety and safe use of Aflibercept in Europe: Postauthorization observational study,
-
DISTRICT ATTORNEY:
Bayer Healthcare Pharmaceuticals Inc.
-
TYPE E:
EPA
-
Ophthalmology
Researcher
- Year 2014
- Comprehensive Care Center Dos de Maig Hospital
Phase IV clinical trial to evaluate the efficacy of aflibercept in naïve patients with retinal angiomatous proliferation lesions (RAP) in the Treat and Extend (TAE) individualized treatment regimen. AFLIRAP studio,
-
DISTRICT ATTORNEY:
Bellvitge Biomedical Research Institute (IDIBELL Foundation)
-
TYPE E:
RD2004
-
Ophthalmology
Researcher
- Year 2014
- Comprehensive Care Center Dos de Maig Hospital
A collaborative and retrospective study on the efficacy and safety of the Dexamethasone implant (Ozurdex) in patients with Diadetic Macular Edema (MDD). EUROPEAN REGISTRATION STUDIO (ARTS),
-
DISTRICT ATTORNEY:
AIBILI
-
TYPE E:
PI
-
Ophthalmology
Researcher
- Year 2014
- Comprehensive Care Center Dos de Maig Hospital
Patient satisfaction study
-
DISTRICT ATTORNEY:
Théa laboratories
-
TYPE E:
EPA
-
- Year 2014
- Comprehensive Care Center Dos de Maig Hospital
A collaborative and retrospective study on the efficacy and safety of the Dexamethasone (Ozurdex) implant in patients with Diadetic Macular Edema (MDD). EUROPEAN REGISTRATION STUDIO (ARTS),
-
DISTRICT ATTORNEY:
AIBILI
-
TYPE E:
PINE TREE
-
- Year 2014
- Comprehensive Care Center Dos de Maig Hospital
Patient satisfaction study
-
DISTRICT ATTORNEY:
Thea laboratories
-
TYPE E:
EPA
Lines of action
- Treatment of retinal diseases with intravitreal medication
- Anti VEGF in diabetic macular edema
- Anti VEGF in central serous chorioretinopathy
- Treatment of Diabetic Retinopathy
- UTI (Intravitreal Therapy Unit)
- New techniques in cataract surgery
- Surgical alternatives to full thickness corneal transplantation
- Microkeratum assisted keratoplasty Anterior and posterior lamellar techniques
